Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Abstract Background Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [complete or partial objective response] beginning within 12 months of treatme...

Full description

Bibliographic Details
Main Authors: Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
Format: Article
Language:English
Published: BMJ Publishing Group 2017-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Talimogene laherparepvec
Durable response rate
Patient-reported outcomes
Online Access:http://link.springer.com/article/10.1186/s40425-017-0276-8

Internet

http://link.springer.com/article/10.1186/s40425-017-0276-8

Similar Items